Investigation Of Weight Loss And Body Composition Changes After Dosing With Either Placebo Or One Of Two Active Drugs

An Exploratory Study to Evaluate Weight Loss, Body Composition Changes, Food Intake and Urine Glucose Excretion in Healthy Obese Subjects Over 8 Weeks of Dosing With GSK189075, GW869682 Versus Placebo

The drugs GSK189075 and GW869682 result in increased caloric losses. This study is investigating how if taken over 8 weeks that affects weight loss, food intake and the composition of the body. The body composition (fat,water, lean mass) is determined using a new investigational MR technology.

Inclusion criteria:

• BMI of 30 - 40kg/m
• Females may be included if they are surgically sterile or post-menopausal

Exclusion criteria:

• Change in body weight >4% in the last 3 months
• History of eating disorders
• had bariatric surgical intervention for obesity
• have type I or II diabetes
• Thyroid disorder not under control
• Renal or hepatobiliary disease
• Excessive alcohol consumption
• Use of drugs of abuse
• donated of blood in the last 3 months